BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1436@pharmaconomics
DTSTAMP:20260707T003825Z
DTSTART;VALUE=DATE:20261001
DTEND;VALUE=DATE:20261002
SUMMARY:CLLS Phase 2 — lasme-cel (estimated date)
DESCRIPTION:Phase 2 trial results for lasme-cel in relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) are due ~ Oct 1\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1627281/000117184326001805/exh_991.htm\n\nTrack it: https://pharmaconomics.com/e/1436
URL:https://pharmaconomics.com/e/1436
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:CLLS catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR